[{"id":"09faeec2-6d19-4e99-bfa8-ce9ad5372038","acronym":"","url":"https://clinicaltrials.gov/study/NCT05843253","created_at":"2023-05-06T15:04:11.203Z","updated_at":"2025-02-25T14:09:40.595Z","phase":"Phase 2","brief_title":"Study of Ribociclib and Everolimus in HGG and DIPG","source_id_and_acronym":"NCT05843253","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C","pipe":" | ","alterations":" PIK3CA mutation • CDKN2A deletion","tags":["PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/22/2024","start_date":" 08/22/2024","primary_txt":" Primary completion: 08/28/2028","primary_completion_date":" 08/28/2028","study_txt":" Completion: 08/28/2034","study_completion_date":" 08/28/2034","last_update_posted":"2025-02-17"},{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"},{"id":"f228ffce-69d8-4696-a61e-6222a211f51d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188508","created_at":"2022-01-12T14:53:32.609Z","updated_at":"2025-02-25T16:17:09.399Z","phase":"Phase 2","brief_title":"Pembrolizumab, Olaparib, and Temozolomide for People with Glioma","source_id_and_acronym":"NCT05188508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type","tags":["EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"ae2cba1f-c1b0-4377-acd9-157b4b00473b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06222203","created_at":"2024-01-24T14:23:14.000Z","updated_at":"2024-07-02T16:34:25.563Z","phase":"","brief_title":"Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)","source_id_and_acronym":"NCT06222203","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CDKN2A • CDKN2B","pipe":" | ","alterations":" CDKN2A mutation","tags":["CDKN2A • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/31/2034","primary_completion_date":" 12/31/2034","study_txt":" Completion: 12/31/2035","study_completion_date":" 12/31/2035","last_update_posted":"2024-06-17"},{"id":"d7d6598c-31e5-4bc3-b406-5e9ff144fe1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03834740","created_at":"2021-01-18T18:56:01.539Z","updated_at":"2024-07-02T16:35:04.374Z","phase":"Phase 1","brief_title":"A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection","source_id_and_acronym":"NCT03834740","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression","tags":["PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 02/18/2022","study_completion_date":" 02/18/2022","last_update_posted":"2024-05-10"},{"id":"fbf4520a-0024-4ad4-aacb-7c70b6344b99","acronym":"","url":"https://clinicaltrials.gov/study/NCT04074785","created_at":"2021-01-18T19:57:29.190Z","updated_at":"2024-07-02T16:35:08.254Z","phase":"Phase 1","brief_title":"Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6","source_id_and_acronym":"NCT04074785","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" CDKN2A • RB1 • CDK4 • CDKN2B","pipe":" | ","alterations":" CDK4 amplification","tags":["CDKN2A • RB1 • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/13/2019","start_date":" 12/13/2019","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 10/24/2025","study_completion_date":" 10/24/2025","last_update_posted":"2024-04-22"},{"id":"cb3171df-fc1d-4edc-a68b-8e666a6750ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04391595","created_at":"2021-01-18T21:11:39.818Z","updated_at":"2024-07-02T16:35:12.669Z","phase":"Phase 1","brief_title":"LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients","source_id_and_acronym":"NCT04391595","lead_sponsor":"Nader Sanai","biomarkers":" CDKN2A • CDK4 • CDKN2B","pipe":" | ","alterations":" CDK4 amplification","tags":["CDKN2A • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/08/2020","start_date":" 07/08/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-03-27"},{"id":"f25984f7-928a-4db7-8a6a-64a803a17f17","acronym":"","url":"https://clinicaltrials.gov/study/NCT02933736","created_at":"2021-01-18T14:24:13.882Z","updated_at":"2025-02-25T15:53:32.297Z","phase":"Phase 1","brief_title":"Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients","source_id_and_acronym":"NCT02933736","lead_sponsor":"Nader Sanai","biomarkers":" CDKN2A • CCND1 • CDK4 • CDKN2B","pipe":" | ","alterations":" CDKN2A deletion","tags":["CDKN2A • CCND1 • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-27"},{"id":"cb935a08-f353-4653-b5c2-b1bea0cd347d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05538572","created_at":"2022-09-14T18:56:05.720Z","updated_at":"2024-07-02T16:35:23.135Z","phase":"Phase 1","brief_title":"A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05538572","lead_sponsor":"Prelude Therapeutics","biomarkers":" HER-2 • KRAS • ER • TP53 • CDKN2A • CDKN2B","pipe":" | ","alterations":" KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type","tags":["HER-2 • KRAS • ER • TP53 • CDKN2A • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRT3645"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-17"},{"id":"9687712d-99d6-4383-b6f4-ea8c602d3944","acronym":"CAT_PB","url":"https://clinicaltrials.gov/study/NCT06065592","created_at":"2023-10-04T16:11:23.801Z","updated_at":"2024-07-02T16:35:34.331Z","phase":"Phase 1","brief_title":"Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms","source_id_and_acronym":"NCT06065592 - CAT_PB","lead_sponsor":"Lebanese University","biomarkers":" PD-1 • VEGFA • CDKN2B • TNFA • CTLA4","pipe":" | ","alterations":" CTLA4 expression","tags":["PD-1 • VEGFA • CDKN2B • TNFA • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTLA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-06"},{"id":"aaf139e5-6f3f-40eb-93b2-665057b40615","acronym":"","url":"https://clinicaltrials.gov/study/NCT06002711","created_at":"2023-08-21T14:09:00.343Z","updated_at":"2024-07-02T16:35:39.575Z","phase":"","brief_title":"Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study","source_id_and_acronym":"NCT06002711","lead_sponsor":"RenJi Hospital","biomarkers":" BRAF • CDKN2A • CDKN2B","pipe":"","alterations":" ","tags":["BRAF • CDKN2A • CDKN2B"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-08-21"},{"id":"43035839-3bf9-43e5-bbd5-afd4d6d1337c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02981940","created_at":"2021-01-18T14:40:08.944Z","updated_at":"2024-07-02T16:35:41.812Z","phase":"Phase 2","brief_title":"A Study of Abemaciclib in Recurrent Glioblastoma","source_id_and_acronym":"NCT02981940","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CDKN2A • RB1 • CDK4 • CDKN2B • CDK6","pipe":" | ","alterations":" CDKN2A deletion • CDK4 amplification • IDH wild-type • RB1 wild-type","tags":["CDKN2A • RB1 • CDK4 • CDKN2B • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • CDK4 amplification • IDH wild-type • RB1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-27"},{"id":"1bcbbcb1-c23e-4cd4-863e-77a53309b4a2","acronym":"NCT-PMO-1601","url":"https://clinicaltrials.gov/study/NCT03110744","created_at":"2021-01-18T15:19:35.640Z","updated_at":"2024-07-02T16:35:52.226Z","phase":"Phase 2","brief_title":"CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma","source_id_and_acronym":"NCT03110744 - NCT-PMO-1601","lead_sponsor":"University Hospital Heidelberg","biomarkers":" CDKN2A • RB1 • CDK4 • CDKN2B","pipe":"","alterations":" ","tags":["CDKN2A • RB1 • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 12/15/2017","start_date":" 12/15/2017","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 12/22/2022","study_completion_date":" 12/22/2022","last_update_posted":"2023-03-27"},{"id":"ee2f1151-0f4f-4a69-942e-a345a7a08618","acronym":"","url":"https://clinicaltrials.gov/study/NCT05497076","created_at":"2022-11-08T19:26:21.936Z","updated_at":"2024-07-02T16:36:05.643Z","phase":"","brief_title":"the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy","source_id_and_acronym":"NCT05497076","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" CDKN2A • RB1 • CCND1 • CCNE1 • CDK4 • CDKN2B • CCND2 • CCND3","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation","tags":["CDKN2A • RB1 • CCND1 • CCNE1 • CDK4 • CDKN2B • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKang (dalpiciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-08-11"},{"id":"e0e1ee61-5bf4-4f29-bfd2-dc13f92d061d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04118036","created_at":"2021-01-18T20:07:39.336Z","updated_at":"2024-07-02T16:36:19.524Z","phase":"Phase 2","brief_title":"Abemaciclib + Pembrolizumab In Glioblastoma","source_id_and_acronym":"NCT04118036","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CDKN2A • RB1 • CDKN2B • CASP3","pipe":" | ","alterations":" CDKN2A deletion • RB1 wild-type","tags":["CDKN2A • RB1 • CDKN2B • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • RB1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Verzenio (abemaciclib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-12-14"}]